Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: Interplay with cerebral blood flow

Molecular Neurodegeneration

Volumn 9, Issue 1, 2014, Pages

  Li, Hongmei ^a,b   Guo, Qinxi ^a   Inoue, Taeko ^a   Polito, Vinicia A ^a   Tabuchi, Katsuhiko ^c   Hammer, Robert E ^b   Pautler, Robia G ^a   Taffet, George E ^a   Zheng, Hui ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer disease; Cerebral amyloid angiopathy (CAA); Cerebral blood flow (CBF); Dutch mutation; Parenchymal plaque; Transverse aortic constriction (TAC)

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID BETA PROTEIN;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN HEMORRHAGE; COMMON CAROTID ARTERY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GENE MUTATION; GENE TARGETING; HIPPOCAMPUS; HOMEOSTASIS; MALE; MALE ANIMAL; MIDDLE AGED; MOUSE; MOUSE MODEL; NONHUMAN; PHENOTYPE; PROTEIN INTERACTION; RIGHT HEMISPHERE; SPATIAL LEARNING; SPIN LABELING; WILD TYPE; WORKING MEMORY; YOUNG ADULT; ANIMAL; ANIMAL BEHAVIOR; BRAIN; BRAIN CIRCULATION; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; VASCULAR AMYLOIDOSIS; VASCULARIZATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCK-IN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MICE;

EID: 84906931766     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-9-28     Document Type: Article

References (55)

1. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Hardy J, Selkoe DJ, Science 2002 297 353 356
2. Vascular pathology in the aged human brain. Grinberg LT, Thal DR, Acta Neuropathol 2010 119 277 290
3. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B, Nat Med 2003 9 907 913
4. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV, Neuron 2004 43 333 344
5. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ, Science 2010 330 1774
6. Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Sagare AP, Bell RD, Zlokovic BV, Cold Spring Harb Perspect Med 2012 2 011452
7. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM, Proc Natl Acad Sci U S A 2001 98 8850 8855
8. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM, Science 2002 295 2264 2267
9. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C, Neurology 2003 61 46 54
10. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA, Brain 2008 131 3299 3310
11. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO, Nat Med 2003 9 448 452
12. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D, Neurology 2005 64 129 131
13. Cerebral amyloid angiopathy and microhemorrhages after amyloid beta vaccination: case report and brief review. Uro-Coste E, Russano de Paiva G, Guilbeau-Frugier C, Sastre N, Ousset PJ, da Silva NA, Lavialle-Guillotreau V, Vellas B, Delisle MB, Clin Neuropathol 2010 29 209 216
14. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, Terasaki T, Hashimoto T, Iwatsubo T, J Neurosci 2009 29 11393 11398
15. Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Van Broeckhoven C, Haan J, Bakker E, Hardy JA, Van Hul W, Wehnert A, Vegter-Van der Vlis M, Roos RA, Science 1990 248 1120 1122
16. APP physiological and pathophysiological functions: insights from animal models. Guo Q, Wang Z, Li H, Wiese M, Zheng H, Cell Res 2011 22 78 89
17. Modulation of gamma-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Rogers K, Felsenstein KM, Hrdlicka L, Tu Z, Albayya F, Lee W, Hopp S, Miller MJ, Spaulding D, Yang Z, Hodgdon H, Nolan S, Wen M, Costa D, Blain JF, Freeman E, De Strooper B, Vulsteke V, Scrocchi L, Zetterberg H, Portelius E, Hutter-Paier B, Havas D, Ahlijanian M, Flood D, Leventhal L, Shapiro G, Patzke H, Chesworth R, Koenig G, Molecular neurodegeneration 2012 7 61
18. Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease. Born HA, Kim JY, Savjani RR, Das P, Dabaghian YA, Guo Q, Yoo JW, Schuler DR, Cirrito JR, Zheng H, Golde TE, Noebels JL, Jankowsky JL, J Neurosci 2014 34 3826 3840
19. Single App knock-in mouse models of Alzheimer's disease. Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC, Nat Neurosci 2014 17 661 663
20. Central CRF system perturbation in an Alzheimer's disease knockin mouse model. Guo Q, Zheng H, Justice NJ, Neurobiol Aging 2012 33 2678 2691
21. Alzheimer's disease-like neuropathology of gene-targeted APP-SLxPS1mut mice expressing the amyloid precursor protein at endogenous levels. Kohler C, Ebert U, Baumann K, Schroder H, Neurobiol Dis 2005 20 528 540
22. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. O'Gorman S, Dagenais NA, Qian M, Marchuk Y, Proc Natl Acad Sci U S A 1997 94 14602 14607
23. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP, Nat Med 1999 5 101 106
24. Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. Wang R, Wang B, He W, Zheng H, J Biol Chem 2006 281 15330 15336
25. Genetic dissection of the amyloid precursor protein in developmental function and amyloid pathogenesis. Li H, Wang Z, Wang B, Guo Q, Dolios G, Tabuchi K, Hammer RE, Sudhof TC, Wang R, Zheng H, J Biol Chem 2010 285 30598 30605
26. Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Park JH, Seo SW, Kim C, Kim GH, Noh HJ, Kim ST, Kwak KC, Yoon U, Lee JM, Lee JW, Shin JS, Kim CH, Noh Y, Cho H, Kim HJ, Yoon CW, Oh SJ, Kim JS, Choe YS, Lee KH, Lee JH, Ewers M, Weiner MW, Werring DJ, Na DL, Ann Neurol 2013 73 584 593
27. Incidence of stroke in people with Alzheimer disease: a national register-based approach. Tolppanen AM, Lavikainen P, Solomon A, Kivipelto M, Soininen H, Hartikainen S, Neurology 2013 80 353 358
28. Alzheimer disease and risk of stroke: a population-based cohort study. Chi NF, Chien LN, Ku HL, Hu CJ, Chiou HY, Neurology 2013 80 705 711
29. Doppler velocity measurements from large and small arteries of mice. Hartley CJ, Reddy AK, Madala S, Entman ML, Michael LH, Taffet GE, Am J Physiol Heart Circ Physiol 2011 301 269 278
30. Doppler estimation of reduced coronary flow reserve in mice with pressure overload cardiac hypertrophy. Hartley CJ, Reddy AK, Madala S, Michael LH, Entman ML, Taffet GE, Ultrasound Med Biol 2008 34 892 901
31. Neurovascular regulation in the normal brain and in Alzheimer's disease. Iadecola C, Nat Rev Neurosci 2004 5 347 360
32. Vascular contribution to Alzheimer disease: predictors of rapid progression. Diomedi M, Misaggi G, CNS Neurol Disord Drug Targets 2013 12 532 537
33. Critical threshold cerebral hypoperfusion causes Alzheimer's disease? de la Torre JC, Acta Neuropathol 1999 98 1 8
34. Overlapping profiles of Abeta peptides in the Alzheimer's disease and pathological aging brains. Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, Ladd TB, Das P, Dickson DW, Golde TE, Alzheimer's research & therapy 2012 4 18
35. Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease. Hellstrom-Lindahl E, Viitanen M, Marutle A, Neurochem Int 2009 55 243 252
36. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ, Nature 1992 360 672 674
37. High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y, Am J Pathol 1994 145 452 460
38. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. Mori H, Takio K, Ogawara M, Selkoe DJ, J Biol Chem 1992 267 17082 17086
39. Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of aβ and tau. Guo Q, Li H, Cole AL, Hur J-Y, Li Y, Zheng H, PLoS One 2013 8 80706
40. Comparative effects of propofol, pentobarbital, and isoflurane on cerebral blood flow and blood volume. Todd MM, Weeks J, J Neurosurg Anesthesiol 1996 8 296 303
41. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C, Am J Physiol Heart Circ Physiol 2002 283 315 323
42. Impaired cerebral autoregulation and vasomotor reactivity in sporadic Alzheimer's disease. den Abeelen AS, Lagro J, van Beek AH, Claassen JA, Curr Alzheimer Res 2014 11 11 17
43. Dynamic cerebral autoregulation in subjects with Alzheimer's disease, mild cognitive impairment, and controls: evidence for increased peripheral vascular resistance with possible predictive value. Gommer ED, Martens EG, Aalten P, Shijaku E, Verhey FR, Mess WH, Ramakers IH, Reulen JP, J Alzheimers Dis 2012 30 805 813
44. Model-based physiomarkers of cerebral hemodynamics in patients with mild cognitive impairment. Marmarelis VZ, Shin DC, Orme ME, Zhang R, Med Eng Phys 2014 36 628 637
45. Three-dimensional cerebral vasculature of the CBA mouse brain: a magnetic resonance imaging and micro computed tomography study. Dorr A, Sled JG, Kabani N, Neuroimage 2007 35 1409 1423
46. Acute hypertension induces oxidative stress in brain tissues. Poulet R, Gentile MT, Vecchione C, Distaso M, Aretini A, Fratta L, Russo G, Echart C, Maffei A, De Simoni MG, Lembo G, J Cereb Blood Flow Metab 2006 26 253 262
47. Beta-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Gentile MT, Poulet R, Di Pardo A, Cifelli G, Maffei A, Vecchione C, Passarelli F, Landolfi A, Carullo P, Lembo G, Neurobiol Aging 2009 30 222 228
48. Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I, Pallante F, Zlokovic B, Yan SS, Lembo G, Hypertension 2012 60 188 197
49. 'Alzheimer-like' pathology in a murine model of arterial hypertension. Carnevale D, Lembo G, Biochem Soc Trans 2011 39 939 944
50. The immunology of stroke: from mechanisms to translation. Iadecola C, Anrather J, Nat Med 2011 17 796 808
51. A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues. Beckstead JH, J Histochem Cytochem 1994 42 1127 1134
52. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Shahbazian M, Young J, Yuva-Paylor L, Spencer C, Antalffy B, Noebels J, Armstrong D, Paylor R, Zoghbi H, Neuron 2002 35 243 254
53. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Vorhees CV, Williams MT, Nat Protoc 2006 1 848 858
54. Developments of a water-maze procedure for studying spatial learning in the rat. Morris R, J Neurosci Methods 1984 11 47 60
55. Doppler evaluation of peripheral vascular adaptations to transverse aortic banding in mice. Li YH, Reddy AK, Taffet GE, Michael LH, Entman ML, Hartley CJ, Ultrasound Med Biol 2003 29 1281 1289